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1. Introduction 
1.1. Burden of liver disease 
In developed countries, the management and treatment of HIV-1 infection was 
revolutionised after the introduction of combined anti-viral therapy (cART) in 1996. The 
major outcome was the reduction of AIDS and AIDS-related deaths (1). Such was the 
success of cART, that now more than 50% of deaths in HIV positive patients on cART are 
not directly related to HIV infection or AIDS (1-3). The D:A:D (data collection on adverse 
events of anti-HIV drugs) study demonstrated that liver disease had become the commonest 
cause of a non-AIDS related death overtaking cardiovascular disease (2). Given the similar 
transmission routes, unsurprisingly nearly two-thirds of deaths were secondary to chronic 
hepatitis C virus (HCV) infection, 17% secondary to chronic hepatitis B virus (HBV) 
infection and 3% due drug-induced liver injury related to cART (2). Other liver-related 
aetiologies amongst HIV positive individuals include alcohol, non-alcohol related liver 
disease (NAFLD), hepatocellular carcinoma (HCC) (Table 1). HIV positive patients present 
with the same clinical sequelae of chronic liver disease as their HIV negative counterparts 
but tend to present at a younger age but with a markedly reduced survival rate after the first 
episode of decompensation (4). In HIV-positive patients with compensated cirrhosis an 
increased mortality rate is associated with age > 50 years, MELD score > 11 and poor control 
of HIV disease (5). 
1.2. Viral aetiologies 
One third of patients with HIV infection are co-infected with chronic HCV, and the majority 
of deaths in HIV-positive patients with ESLD can be attributable to HCV infection(6). HCV 
is transmitted via contaminated blood or blood products. At-risk groups include 
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intravenous drug users, patients with haemophilia who were exposed to contaminated 
infusions of plasma derived factor VIII or X concentrate, men who have sex with men 
(MSM) and individuals who have sex with IVDUs (7). Vertical transmission is also possible 
and is more likely if the mother is HIV-positive. A more recent trend is the increase in the 
number of new cases of acute HCV in MSM who are HIV-positive acquired via sexual 
transmission (8, 9).  
HIV infection clearly affects HCV-related liver disease. The combination of HIV/HCV co-
infection is associated with a reduced rate of spontaneous HCV RNA clearance and 
therefore an increased likelihood of developing chronic HCV infection (10). Once HCV 
infection is established then a more rapid fibrosis progression rate is evident (11). The 
development of cirrhosis tends to occur on average 15 years earlier than in HCV mono-
infected individuals (12). Predictors of fibrosis progression include detectable HIV viraemia, 
low CD4+ counts, baseline necro-inflammatory activity on liver biopsy and increased 
alcohol consumption (>50g per day) (13, 14). HIV/HCV co-infected patients have a poorer 
survival following the first episode of decompensation; median estimated survival of only 
13 months (4). Mechanisms for this accelerated fibrosis rate appear to be multi-factorial and 
include a weaker adaptive immune response of CD8+ cells, the increased number of the pro-
fibrogenic CD8+ cells and relative reduction in CD4+ cells, the presence of insulin resistance 
and reduction of interleukin – 10 expression(15-19, 19, 20). The HIV virus cannot enter 
hepatocytes directly but it can upregulate pro-fibrotic pathways e.g. transforming growth 
factor B-1 which further activates hepatic stellate cells (10).  
Treatment of HCV in patients with HIV is more difficult compared to HCV-monoinfected 
patients and is associated with an increased side-effect profile. At present pegylated 
interferon and ribavirin are the only licensed medications for the treatment of HCV in 
HIV/HCV co-infected patients. Compared to HCV mono-infected patients, end-of-treatment 
(29-62%) and sustained virological response rates (SVR) are inferior (17-35%) (21-26). The 
use of the newer protease inhibitors in the treatment of HCV in HIV-positive patients has 
only been limited to the trial arena. Preliminary data from the 110 Phase 2 study 
demonstrate similar outcomes to monoinfection with 74% SVR 12 in telaprevir triple 
therapy group (n=38) vs 45% standard of care (n=22); with no breakthrough in HIV RNA 
and similar side effect profile to monoinfection treated with telaprevir.  
HIV-positive patients commonly exhibit evidence of previous HBV infection, whereas 10% 
of the HIV-positive population have evidence of chronic HBV infection (27). Vertical 
transmission of HBV remains the most common route of infection worlwide, whilst sexual 
transmission and percutaneous transmission is more likely in Europe and North America 
(28, 29). HIV-positive patients that contract HBV infection are less likely to clear the virus, a 
quarter of patients will develop chronic HBV infection, especially those with low CD4+ cell 
counts (30). HIV/HBV co-infected patients also have increased HBV DNA viral loads 
compared to HBV mono-infected patients, which also translates into an increased risk of 
developing HCC (31). 
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HIV/HBV co-infection related – morbidity is considerably less when compared to HIV/HCV 
co-infected patients. This is due to the use of nucleoside and nucleotide reverse-transcriptase 
inhibitors (lamivudine, emtricitabine and tenofovir) that are used in cART regimens and 
have both anti-HIV and anti-HBV activity.   
Given that co-infection with HBV and HCV are the leading causes of liver disease amongst 
HIV-positive patients, the incidence of hepatocellular carcinoma (HCC) is expected to rise 
and the MORTAVIC and French Mortalite studies have both demonstrated an increasing 
number of deaths attributable to HCC (6, 32). HIV-positive patients presenting with HCC 
are younger at presentation (52 versus 64 years, p<0.0001), are more likely to be 
symptomatic at presentation, have multiple tumours at presentation, and have advanced 
disease compared to HIV-negative patients (31, 33). 
1.3. Non-viral aetiologies 
Awareness of drug-induced liver injury or cART-induced hepatotoxicity is increasing. 
Deciding on the culprit drug is often difficult because of the use of combination therapies. 
Recognised patterns of liver injury include hypersensitivity, idiosyncratic hepatotoxicity, 
mitochondrial toxicity, an immune reconstitution syndrome and hepato-steatosis (34-38). 
Acute liver failure resulting from cART is uncommon. The development of non-cirrhotic 
portal hypertension (NCPH) secondary to cART in particular to didanosine is an emerging 
disease entity (39). The pathogenesis of NCPH appears to be linked to a pro-thrombotic 
state, an acquired protein S deficiency. The spectrum of histological findings include 
nodular regenerative hyperplasia, hepatoportal sclerosis, peri-portal fibrosis and sclerosing 
portal venopathy (40-42).  
The D:A:D study also highlighted that the prevalence of the metabolic syndrome has 
increased over the last decade from 19% in 2000-2001 to 42% in2006-2007 (43). This is likely 
to result in an increase in the prevalence of NAFLD, given that NAFLD is the hepatic 
manifestation of the metabolic syndrome. There is limited data available on the risk factors 
for NAFLD in HIV-positive patients but attention has focused on the role of cART because 
of its negative effects of insulin resistance, glucose metabolism and lipid metabolism. 
Central adiposity, male sex, low serum high-density lipoprotein levels, raised triglycerides 
levels and an increased ratio of alanine aminotransferase to aspartate aminotransferase have 
been suggested as risk factors for the development of NAFLD (44). 
1.4. Selection criteria for liver transplantation 
Irrespective of liver aetiology, HIV-positive patients with liver disease need to be managed 
in a multi-disciplinary environment by an experienced HIV physician and Hepatologist. 
Given their rapid disease kinetic, HIV-positive patients with end stage liver disease (ESLD) 
need to be identified early. Specific guidelines for LT in HIV-positive patients evolved  as 
our understanding of the specific issues faced by this cohort improves. Current US National 
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Institutes of Health multi-center trial guidelines for LT in HIV positive patients with chronic 
liver disease are listed in Table 2. UK guidelines have similar requirements. 
The Model for End-Stage Liver Disease (MELD) score has been adopted by transplant 
centers across Europe and North America to ensure the appropriate allocation of organs to 
those at the highest risk of death (45). Although MELD has been well validated in the HIV- 
negative patients, there have been mixed reports on its sensitivity in HIV-positive patients 
with ESLD (46). One prospective study reported similar MELD scores at the initial LT 
assessment for HIV-positive and HIV negative patients despite those with HIV having a 
significantly shorter cumulative survival time (880 versus 1427 days, p=0.04) (47). Another 
observation made by the same study was that the MELD score did not differentiate between 
survivors and non-survivors (13 versus 15, p = 0.6).  Two more recent studies, both 
prospective, however have suggested that the MELD score may actually be a sensitive 
predictor of patient outcome (47, 48). Multivariate analysis of predictive factors of mortality 
demonstrated that the MELD score was independently associated with death (HR per 5-U 
increase 1.53, p<0.001). The MELD score also remained predictive of death on subgroup 
analysis of HIV/HCV patients (without HCC) and on comparison with HIV negative 
historical controls, the mortality rates were significantly higher for HIV-positive patients in 
each MELD category (48). In the second study, which matched 167 HIV-positive patients 
with 792 HIV-negative patients the baseline MELD score was the only significant predictor 
of pre-LT mortality in HIV-positive patients after controlling for CD4+ counts and HIV RNA 
levels (47).  
Optimal control of HIV disease is an important prerequisite for HIV-positive patients 
undergoing consideration for LT. In patients with portal hypertension, splenic sequestration 
of T lymphocytes can lead to a fall in the CD4+ T cell count. In such cases a CD4+ cell count 
> 100 cells/uL is acceptable. A fall in the CD4+ cell count can also be precipitated by the use 
of pegylated interferon. In our opinion, CD4+ T cell percentages may represent a more 
sensitive indicator of immune reconstitution in HIV-positive patients with portal 
hypertension. HIV-positive patients undergoing evaluation for LT also require an 
undetectable HIV viral load (< 50 copies/mL) except for those that presently acutely.  The 
inability to achieve an undetectable HIV RNA viral load before LT has been associated with 
an increased mortality rate (HR 3.5, p<0001)(48). In addition to good therapeutic options 
available in the pre-transplant period, HIV-positive patients require future cART options 
based upon their previous regimens and HIV phenol- genotype resistance testing. It is not 
inconceivable that certain HIV-positive patients may not be able to tolerate cART 
medications pre-LT due to brittle liver synthetic function. This group should not be 
automatically excluded from LT as long as HIV control is deemed possible post LT by the 
multidisciplinary team. cART intolerance post-LT, however has been identified as an 
important predictor of survival (49).    
A thorough knowledge of past opportunistic infections is required. A distant history of an 
opportunistic infection in a patient that was not taking cART is not a contraindication to LT 
unless there is no effective treatment available for possible recurrence post-LT. Absolute 
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contra-indications include multidrug resistant HIV, resistant fungal infections, chronic 
intestinal cryptosporidiosis, progressive multi-focal leukoencephalopathy and central 
nervous system lymphoma.  
2. Post liver transplantation 
Standard surgical techniques with conventional arterial, venous and biliary anastomosis are 
recommended. One concern highlighted is the possible risk of transmission of HIV to the 
surgical team. The risk of HIV however is low and is substantially lower than the risk of 
transmission of HBV and HCV (50). In the event of HIV exposure, current regimens provide 
effective prophylaxis (51). As HIV infection is associated with a pro-thrombotic state, 
concerns have been raised regarding an increased risk of vascular complications post 
transplantation (52). Recent data from our Institution demonstrated an increased an 
increased incidence of hepatic artery thrombosis compared to HIV negative patients (12% 
vs. 3.2%, p=0.016) (53). Given the increased pro-thrombotic risk, the introduction of 
prophylactic subcutaneous heparin (5000 units every 8 hours) is recommended once the 
international normalised ration (INR) is below 1.5 and the platelet count is greater than 50 x 
109 cells/L. 
Immunosuppression should be tailored to the individual taking into account aetiology of 
liver disease, renal function, risk factors for the metabolic syndrome and specifically to HIV 
patients the possible interactions with combined anti-viral therapy (cART) medications. 
Dual immunosuppression with calcineurin inhibitors (CNIs) and cortico-steroids is 
recommended post-LT. Target trough levels in the first 3 months should be the same as HIV 
negative patients (cyclosporin, 100-250 ng/ml; tacrolimus, 8-10ng/ml). Utilising data from 
HCV mono-infected patients post-LT, rapid withdrawal of cortico-steroids should be 
avoided due to the association of a more severe recurrence of HCV (54). We therefore 
recommend that prednisolone, which is usually commenced at 20mg daily, be withdrawn 
by a slow taper at 3 months. Anti-fungal prophylaxis (fluconazole 50mg daily) should be 
given for a minimum of 3 months post-LT. Episodes of acute cellular rejection (ACR) should 
also be managed as one would in HIV negative patients namely moderate-severe episodes 
be treated with a 3-day course of intravenous methylprednisolone (1g daily). Consideration 
of the introduction of mycophenalate mofetil (MMF) after the 2nd episode of ACR is 
recommended. 
Both tacrolimus and cyclosporin are metabolised via the P450 cytochrome. In addition, non-
nucleoside reverse-transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), which 
are commonly part of cART regimens, are also metabolised by the same pathway, therefore 
increasing the risk of drug – drug interactions. NNRTIs (e.g. efavirenz) decrease serum CNI 
concentrations by induction of the P450 cytochrome whilst PIs (e.g. ritonavir and lopinavir) 
are inducers resulting in increased CNI concentrations (55). We have used tacrolimus doses 
as low as 1mg per week in certain individuals. Raltegravir, a novel HIV-1 integrase 
inhibitor, is not metabolised via the P450 cytochrome and has been used successfully post 
transplantation in combination with nucleoside reverse-transcriptase inhibitors and 
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standard CNI doses (56). Meticulous monitoring and surveillance is required to reduce the 
possibility drug-drug interactions and toxicity.  
2.1. Outcomes post liver transplantation 
Initial case series of HIV positive patients undergoing liver transplantation were associated 
with poor outcomes (57, 58). It is important to note that this was before the introduction of 
cART regimens. Retrospective data since has however demonstrated an increasing 
understanding of the complexities faced by this unique patient cohort. To date, the largest 
study analysed data provided by the US United Network for Organ Sharing LT database 
(1997-2006) and identified 138 HIV-positive patients (59). Overall survival rates were 
inferior in the HIV positive cohort compared to a comparative HIV negative cohort (n = 
30.520) at 2- and 3-years post transplant (70% and 60% vs 81% and 77%, p < 0.047). 
Considerable data however was missing from the HIV cohort raising the possibility that 
HIV infection may not have been optimally treated prior to LT.   
2.2. Hepatitis C co-infection 
The present literature clearly demonstrates that outcomes in HIV/HCV co-infected patients 
is suboptimal when compared to other aetiologies. Studies to date have only described small 
numbers from single centres. Survival rates have ranged between 64-88% at 1 year and 33-
51% at 5 years (49, 60-62). The only prospective cohort study of 89 HIV/HCV co-infected 
patients and 235 HCV mono-infected controls performed at 17 US centers which was 
recently published, warrants further analysis (63). The authors evaluated the 2 cohorts for a 
median 2.7 years and 2.4 years respectively (ref). Compared to HCV controls, HIV/HCV co-
infected patients were younger (49 vs. 54 years, p<0.0001), had lower BMI at listing (25 vs. 28 
kg/m2, p<0.0001), more HBV co-infection (6% vs. 1%, p=0.02), were more likely to receive a 
non-heart beating graft (17% vs. 4%, p = 0.0002), longer median warm ischaemia time (41 vs. 
21 minutes, p =0.001) and less use of tacrolimus-based (versus cyclosporine) initial 
immunosuppression (58% vs. 80%, p<0.0001). 1- and 3-year patient survival rates were 76% 
and 60% in HIV/HCV cohort compared to 92% and 79% in the HCV cohort (p<0.001). Graft 
loss was also significantly higher in the HIV/HCV cohort (p<0.001). Multivariate analysis 
identified HIV infection as the only baseline factor associated with increased risk of death 
(HR 2.3, p = 0.002) and graft loss (HR 1.9, p = 0.01). Analysis of the HIV/HCV co-infected 
cohort only identified that receipt of a combined kidney-liver transplant (HR 3.8, p=0.003), 
BMI<21 kg/m2 at enrolment (HR = 3.2, p=0.01), receipt of an anti-HCV positive donor (HR 
2.5, p=0.03), and older donor age (HR 1.3 per decade, p=0.04) were significant predictors of 
reduced graft survival. A previous study identified a MELD score > 20, intolerance of cART 
post transplantation and high post-transplant HCV viral loads as predictors of mortality 
post-LT (49). The cumulative incidence of acute cellular rejection (ACR) requiring treatment 
was significantly higher in HIV/HCV patients compared to HCV-mono-infected patients 
(39% vs. 24% at year 3, HR 2.1, p=0.01)(63). 50% of the cases of ACR occurred within the first 
21 days following LT. 
 
The Role of Liver Transplantation in HIV Positive Patients 265 
Recurrence of HCV post-LT is universal but an accelerated disease course is well recognised 
in HIV/HCV co-infected patients (62, 64). HCV recurrence, especially the aggressive severe 
fibrosing cholestatic variant of recurrent hepatitis C (FCH) and sepsis are the leading causes 
of death post-LT amongst HIV/HCV co-infected patients (61, 62, 65-68). Although no reliable 
markers are available to identify patients who will develop FCH, higher HCV viral loads 
immediately after LT at week 1 and week 2 may be an indicator for those at risk (69). A 
French study highlighted the rapid fibrosis progression rates in HIV/HCV co-infected 
patients (2.4 versus 1.4 score, p=0.01) at 24 months post-LT (62). The likelihood of 
progression to a fibrosis score ≥ 2 was also significantly higher in HIV/HCV co-infected 
patients (p<0.0001). 
Re-treatment of HCV recurrence post-LT is associated with an increased side-effect profile 
and poorer treatment outcomes compared to HCV patient’s pre-LT. Pegylated interferon 
and ribavirin remain the ‘standard of care’ for a minimum of 48 weeks irrespective of viral 
genotype. Treatment for recurrent HCV post-LT in our institution is instigated when 
histological disease is demonstrable (F≥2) although some groups have commenced 
treatment within 90 days of LT (70, 71). The concurrent use of didanosine and ribavirin is 
not recommended due to increased risk of mitochondrial toxicity (72). cART regimens that 
contain abacavir should also be avoided due to the impairment of ribavirin phosphorylation 
(73).  
2.3. Hepatitis B co-infection and non-viral aetiologies 
Patients co-infected with HBV and non-viral aetiologies including those that present with 
acute liver failure, have excellent short and long-term outcomes post LT. Reported median 
survival at 1 year ranges between 75-100% and 100% at 5 years (74)(75). The largest 
prospective study to date in HIV/HBV co-infected patients was conducted in 21 patients for 
a median of 42 months with no patient suffering graft loss (76).  
The key difference between HIV/HBV and HIV/HCV co-infected patients is the presence of 
highly potent anti-viral agents against HBV in the therapeutic armamentarium. Patients co-
infected with HBV and receiving cART will undoubtedly be receiving an oral 
nucleoside/nucleotide analogue that will have anti-viral actions against both HIV and HBV. 
Tenofovir in conjunction with emtricitabine (Truvada) is recommended (76, 77). The use of 
these highly efficacious, potent oral agents results in the majority of patients undergoing LT 
with an undetectable HBV viral load. Immuno-prophylaxis with Hepatitis B 
Immunoglobulin (HBIg) is also recommended in the post LT period indefinitely. Reported 
data on the use of HBIg and oral anti-viral agents has demonstrated that this combination is 
highly effective at preventing HBV recurrence even in those who have a detectable HBV 
viral load at the time of LT (78). Data on patients with HIV and non-viral liver disease 
undergoing LT is limited. Our experience suggests that these patients have similar survival 
rates as HIV negative patients (74).     
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2.4. Hepatocellular carcinoma 
Studies specifically evaluating outcomes of LT in HIV positive patients with HCC have been 
limited. One such study compared 21 HIV positive patients with 65 HIV negative patients 
(79). The authors demonstrated a trend towards a higher drop-out rate on the waiting-list 
amongst HIV positive patients (23% vs 10%, p = 0.08) with 16 HIV positive and 58 HIV 
negative patients eventually undergoing LT. HIV positive patients were younger at the time 
of LT (50 versus 58 years, p<0.002) and following LT, observed survival was comparable at 1 
and 3 years (81% and 74% versus 93% and 85%, p=0.07). HCC recurred in 5 HIV positive 
patients (31%) and in 9 HIV negative patients (15%) at a median time of 11 and 18 months 
respectively. Predictive factors for HCC recurrence before LT included Child Pugh C 
(p=0.003), being outside the Milan criteria radiologically (p=0.0008) and AFP progression > 
15 ug/L per month on the waiting list (p=0.005). Factors predictive of HCC recurrence post 
LT which took into account pathological factors included those outside the Milan criteria 
(p=0.01), those outside the UCSF criteria (p=0.03) and those with evidence of satellite 
nodules (p=0.03) and microscopic (p=0.005) or macroscopic vascular invasion (p=0.001). 
Further studies are required to evaluate the influence of HIV infection on the impact of HCC 
post-LT but this indication in the HIV population will become more relevant.  
2.5. HIV disease post transplant 
At present no standardised cART regimen is utilised, but instead is tailored to the 
individual patient reflecting known resistance and mutations. The re-introduction of cART 
post-LT also varies between individual centers, with some continuing cART throughout the 
transplant period whilst others re-introduce the medication between 4-14 days. We 
recommend that cART medication should be re-introduced once liver graft function has 
normalised thereby avoiding the possibility of confusion with the other causes of graft 
dysfunction immediately post-LT. 
In a recent study of HIV/HCV patients bacterial infections were identified as the principal 
aetiological agents of post-LT infections and viral infections were secondary to 
uncomplicated herpes simplex virus (HSV) infections (80). Risk factors associated with 
severe infections included a pre-LT MELD score of > 15 ( HR 3.5, 95% CI 1.7-7.1, p = 0.001), 
history of category C AIDS-defining events (HR4.0, 1.9-8.6, p<0.001) and non-tacrolimus 
based immunosuppression (HR 2.5, 1.3-4.8, p=0.006). The same study also suggested that 
opportunistic infections namely CMV disease, disseminated HSV, invasive fungal infections 
and tuberculosis were increased in HIV positive patients, affecting 11% of their cohort. It is 
important to note these ‘opportunistic’ infections however can occur in HIV negative 
patients post LT. This study also did not have a HIV negative comparative group therefore 
not allowing the authors to be able to demonstrate that these deemed opportunistic 
infections were due to HIV infection only. Reassuringly reported data from other studies 
fails to demonstrate a higher incidence of opportunistic infections in comparison to HIV 
negative patients (81). 
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• Viral: 
Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E 
CMV 
HSV 
• Non-viral: 
Alcohol 
cART induced liver injury (e.g. NNRTI, NRTI, PI) 
Immune reconstitution 
Non-alcohol related fatty liver disease 
Non-cirrhotic portal hypertension 
Opportunistic infections 
cART, combined anti-retroviral therapy; CMV, cytomegalovirus; HSV, herpes simplex virus; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor  
Table 1. Causes of liver disease in HIV-positive individuals 
• The criteria for liver transplantation are met 
• CD4+ cell count > 100 cells/uL (> 200 cells/uL with a previous history of 
opportunistic complications). 
• HIV viral load < 50 copies/mL ( using ultrasensitive  Amplicor Monitor PCR 
assay) 
• Absence of AIDS-defining illness 
• Absence progressive multi-focal leukoencephalopathy, chronic  intestinal 
cryptosporidiosis (> 1 month) or primary CNS lymphoma  
Table 2. Criteria for Liver Transplantation in HIV-positive individuals 
3. Conclusion 
HIV-positive patients established on cART are expected to have good long-term outcomes. 
Given the success of cART, more patients are likely to present with the long-term sequelae 
of ESLD. In an era of organ/donor shortage, more of these patients are likely to present as 
potential candidates for liver transplantation. Our understanding of the issues faced by this 
patient cohort both pre- and post-liver transplantation continues to improve but challenges 
remain in the management of HIV-HCV coinfection. The data discussed in this article 
certainly represents a learning curve of the experience of this patient cohort. Liver 
transplantation in HIV-positive patients is a viable option and should be considered for  
carefully selected patients in transplant units with multi-disciplinary expertise. 
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